News
TAMPA, FL / ACCESS Newswire / July 29, 2025 / The explosive popularity of GLP-1 weight-loss medications such as Ozempic®, ...
In a study on people with obesity and asthma, researchers saw “significant” improvements in the asthma scores of people who ...
7d
Everyday Health on MSNCan GLP-1 Patches Really Help You Lose Weight?
Experts say there’s no evidence GLP-1s can be absorbed through the skin — and these patches don’t contain the FDA-approved ...
In a trial, the daily GLP-1 pill showed "significant" results and similar side effects to injectable GLP-1 drugs like Ozempic and Mounjaro, the pharmaceutical company says.
The appetite-suppressing medications reduce consumption of processed and sugary foods, creating new risks and opportunities.
GLP-1s (glucagon-like peptide-1 receptor agonists), like Wegovy, Ozempic, or generic liraglutide, have helped you reach your ...
Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...
Weight-loss drugs like semaglutide and tirzepatide may help shrink waistlines, but new research shows they fail to boost ...
Scientists Warn: Popular Weight Loss Drugs Like Ozempic Fail To Provide Key Long-Term Health Benefit
Though GLP-1 drugs drive major weight loss, researchers warn they may fall short in improving heart and lung fitness. Protecting muscle mass may be key to unlocking their full health potential. Widely ...
Thousands find weight loss relief on Zepbound. Now, they face a choice: Try a different medicine that may have adverse side effects or stop treatment.
17d
MedPage Today on MSNGLP-1 Therapy Helps Amplify Bariatric Surgery Weight Loss, But Timing Matters
In 568 patients who underwent bariatric surgery, those who also used a GLP-1 receptor agonist during the preoperative and postoperative period experienced significantly greater weight loss -- a 33% ...
A new study suggests that eating more protein while taking GLP-1 medications could help prevent muscle loss, a common side ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results